Leland Gershell
Stock Analyst at Oppenheimer
(4.18)
# 530
Out of 4,479 analysts
88
Total ratings
33.33%
Success rate
28.89%
Average return
Main Sectors:
32 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Maintains: Outperform | $32 → $40 | $16.48 | +142.72% | 7 | Jun 14, 2024 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Outperform | $29 | $15.77 | +83.89% | 3 | Jun 6, 2024 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $55 → $74 | $46.07 | +60.63% | 6 | Jun 4, 2024 | |
| IMVT Immunovant | Maintains: Outperform | $50 → $46 | $27.51 | +67.21% | 2 | Jun 3, 2024 | |
| CAPR Capricor Therapeutics | Initiates: Outperform | $14 | $4.84 | +189.26% | 1 | May 17, 2024 | |
| EPIX ESSA Pharma | Maintains: Outperform | $17 | $5.12 | +232.03% | 1 | May 16, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $65 → $59 | $42.29 | +39.51% | 6 | May 13, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $36 → $31 | $13.21 | +134.67% | 4 | May 9, 2024 | |
| TARA Protara Therapeutics | Maintains: Outperform | $26 → $30 | $2.09 | +1,335.41% | 2 | Apr 22, 2024 | |
| AVTX Avalo Therapeutics | Upgrades: Outperform | $35 | $12.61 | +177.56% | 2 | Apr 16, 2024 | |
| VERU Veru Inc. | Reiterates: Outperform | $7 → $5 | $0.88 | +469.02% | 5 | Apr 15, 2024 | |
| CUE Cue Biopharma | Maintains: Outperform | $10 | $1.02 | +880.39% | 1 | Apr 9, 2024 | |
| NCNA NuCana | Reiterates: Outperform | $100 | $2.77 | +3,510.11% | 5 | Apr 1, 2024 | |
| CALC CalciMedica | Maintains: Outperform | $14 | $4.25 | +229.41% | 4 | Apr 1, 2024 | |
| XERS Xeris Biopharma Holdings | Initiates: Outperform | $5 | $2.17 | +130.41% | 1 | Mar 28, 2024 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $9 | $2.89 | +211.42% | 2 | Mar 21, 2024 | |
| LUMO Lumos Pharma | Maintains: Outperform | $16 | $2.26 | +607.03% | 4 | Mar 8, 2024 | |
| PDSB PDS Biotechnology | Maintains: Outperform | $23 → $20 | $3.03 | +560.07% | 3 | Nov 15, 2023 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Perform | n/a | $243.32 | - | 5 | Oct 11, 2023 | |
| MIST Milestone Pharmaceuticals | Maintains: Outperform | $16 → $13 | $1.34 | +870.15% | 3 | Apr 12, 2023 | |
| ASND Ascendis Pharma | Downgrades: Perform | n/a | $133.98 | - | 6 | Apr 5, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Outperform | $5 → $4 | $0.59 | +578.66% | 1 | Mar 24, 2023 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Perform | n/a | $82.13 | - | 2 | Feb 22, 2023 | |
| ARGX argenx SE | Initiates: Perform | n/a | $434.22 | - | 1 | Oct 12, 2022 | |
| CLNN Clene | Downgrades: Perform | n/a | $0.36 | - | 1 | Oct 4, 2022 | |
| ACST Acasti Pharma | Initiates: Outperform | $36 | $2.92 | +1,132.88% | 3 | Dec 22, 2021 | |
| WINT Windtree Therapeutics | Initiates: Outperform | $7,200 | $3.21 | +224,199.07% | 1 | Jun 4, 2021 | |
| TRVN Trevena | Initiates: Perform | n/a | $0.21 | - | 1 | Mar 15, 2021 | |
| TEVA Teva Pharmaceutical | Initiates: Perform | n/a | $16.34 | - | 1 | Nov 25, 2020 | |
| CASI CASI Pharmaceuticals | Initiates: Outperform | n/a | $5.40 | - | 1 | Oct 23, 2020 | |
| VCNX Vaccinex | Maintains: Outperform | $4,620 → $1,470 | $6.38 | +22,940.75% | 2 | Sep 25, 2020 | |
| AMRN Amarin Corporation | Upgrades: Perform | n/a | $0.69 | - | 1 | Mar 31, 2020 |
UroGen Pharma
Jun 14, 2024
Maintains: Outperform
Price Target: $32 → $40
Current: $16.48
Upside: +142.72%
Catalyst Pharmaceuticals
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $15.77
Upside: +83.89%
Crinetics Pharmaceuticals
Jun 4, 2024
Maintains: Outperform
Price Target: $55 → $74
Current: $46.07
Upside: +60.63%
Immunovant
Jun 3, 2024
Maintains: Outperform
Price Target: $50 → $46
Current: $27.51
Upside: +67.21%
Capricor Therapeutics
May 17, 2024
Initiates: Outperform
Price Target: $14
Current: $4.84
Upside: +189.26%
ESSA Pharma
May 16, 2024
Maintains: Outperform
Price Target: $17
Current: $5.12
Upside: +232.03%
Soleno Therapeutics
May 13, 2024
Maintains: Outperform
Price Target: $65 → $59
Current: $42.29
Upside: +39.51%
Viridian Therapeutics
May 9, 2024
Maintains: Outperform
Price Target: $36 → $31
Current: $13.21
Upside: +134.67%
Protara Therapeutics
Apr 22, 2024
Maintains: Outperform
Price Target: $26 → $30
Current: $2.09
Upside: +1,335.41%
Avalo Therapeutics
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $12.61
Upside: +177.56%
Veru Inc.
Apr 15, 2024
Reiterates: Outperform
Price Target: $7 → $5
Current: $0.88
Upside: +469.02%
Cue Biopharma
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $1.02
Upside: +880.39%
NuCana
Apr 1, 2024
Reiterates: Outperform
Price Target: $100
Current: $2.77
Upside: +3,510.11%
CalciMedica
Apr 1, 2024
Maintains: Outperform
Price Target: $14
Current: $4.25
Upside: +229.41%
Xeris Biopharma Holdings
Mar 28, 2024
Initiates: Outperform
Price Target: $5
Current: $2.17
Upside: +130.41%
Trevi Therapeutics
Mar 21, 2024
Maintains: Outperform
Price Target: $9
Current: $2.89
Upside: +211.42%
Lumos Pharma
Mar 8, 2024
Maintains: Outperform
Price Target: $16
Current: $2.26
Upside: +607.03%
PDS Biotechnology
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $3.03
Upside: +560.07%
Alnylam Pharmaceuticals
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $243.32
Upside: -
Milestone Pharmaceuticals
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.34
Upside: +870.15%
Ascendis Pharma
Apr 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $133.98
Upside: -
X4 Pharmaceuticals
Mar 24, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $0.59
Upside: +578.66%
BioMarin Pharmaceutical
Feb 22, 2023
Downgrades: Perform
Price Target: n/a
Current: $82.13
Upside: -
argenx SE
Oct 12, 2022
Initiates: Perform
Price Target: n/a
Current: $434.22
Upside: -
Clene
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.36
Upside: -
Acasti Pharma
Dec 22, 2021
Initiates: Outperform
Price Target: $36
Current: $2.92
Upside: +1,132.88%
Windtree Therapeutics
Jun 4, 2021
Initiates: Outperform
Price Target: $7,200
Current: $3.21
Upside: +224,199.07%
Trevena
Mar 15, 2021
Initiates: Perform
Price Target: n/a
Current: $0.21
Upside: -
Teva Pharmaceutical
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $16.34
Upside: -
CASI Pharmaceuticals
Oct 23, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.40
Upside: -
Vaccinex
Sep 25, 2020
Maintains: Outperform
Price Target: $4,620 → $1,470
Current: $6.38
Upside: +22,940.75%
Amarin Corporation
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $0.69
Upside: -